TITLE

INTERMUNE/BOEHRINGER TO COMMERCIALIZE INTERFERON/GAMMA-1B

PUB. DATE
May 2001
SOURCE
Worldwide Biotech;May2001, Vol. 13 Issue 5, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the international strategic partnership between InterMune and Boehringer Ingelheim International GmbH to develop and commercialize interferon gamma-1b under Boehringer Ingelheim's trade name Imukin.
ACCESSION #
4425597

 

Related Articles

  • Drug Developments and STD News.  // AIDS Patient Care & STDs;Sep2003, Vol. 17 Issue 9, p487 

    Reports on various drug developments and news about sexually transmitted diseases as of September 2003. Questions on the efficacy of interferon and ribavirin as early hepatitis C treatment; Dimagi's development of a device designed to protect the identity of individuals who receive HIV tests;...

  • OCTOPLUS\BIOLEX DEVELOPING LOCTERON.  // Worldwide Biotech;Apr2005, Vol. 17 Issue 4, p1 

    Focuses on the deal between drug delivery and development company OctoPlus and protein therapeutics firm Biolex Inc. to co-develop a controlled release formulation of recombinant human alfa interferon called Locteron. Characteristics of the drug; Terms of the deal; Background information on the...

  • Drug Developments and STD News.  // AIDS Patient Care & STDs;May2003, Vol. 17 Issue 5, p257 

    Presents news developments related to drug developments and sexually transmitted diseases as of May 2003. Possible benefits of interferon to HIV infections; Transmission of HIV infections from female to female; Warnings against the use of erectile dysfunction drug Viagra.

  • New Genetic Discoveries and Treatment for Hepatitis C. Pacanowski, Michael; Amur, Shashi; Zineh, Issam // JAMA: Journal of the American Medical Association;5/9/2012, Vol. 307 Issue 18, p1921 

    The authors discuss the discovery of Chronic hepatitis-C (HC) pharmacogenetics and its use in future drug development in the U.S. They offer a background on the milestones in HC virus drug development. They also explore some studies on the relevance of the pharmacogenomic evolution in CHC,...

  • Drug Targets in Hepatitis B Virus Infection. Stein, Lance L.; Loomba, Rohit // Infectious Disorders - Drug Targets;Apr2009, Vol. 9 Issue 2, p105 

    Hepatitis B virus infection (HBV) is a significant global health problem. Despite the success of universal hepatitis B vaccination in many countries, more than 350 million individuals worldwide are chronically infected and 15- 40% of those will develop cirrhosis and/or hepatocellular carcinoma...

  • Sequence variation of the HVR1 region of Hepatitis C virus in response to interferon-a and ribavirin treatment. Al-Qahtani, Ahmed A.; Rubino, Salvatore; Al-Ahdal, Mohammed N. // Journal of Infection in Developing Countries;May2011, Vol. 5 Issue 5, p370 

    Introduction: Hepatitis C virus (HCV), which is a major cause of liver diseases worldwide, undergoes genetic variation during the course of infection. The aim of this study was to examine sequence variations within the HVR1 region of HCV genotype 4 in infected Saudi patients treated with a...

  • MIRACLE CURES THAT WEREN'T.  // Fortune International (Europe);3/22/2004, Vol. 149 Issue 5, p56 

    The article looks at possible cures for cancer that were developed in the 1990s and that failed to deliver on expectations. Soon after Wilhelm Roentgen's discovery of X-rays in 1895, some doctors predicted that the high-energy waves from exotic "cyclotrons" could be used to kill most cancerous...

  • Perspective: Miles to go before we sleep. Rice, Charles // Nature;6/9/2011 Supplement, Vol. 474 Issue 7350, pS8 

    In this article, the author discusses the treatment of hepatitis C virus (HCV) infection using the newly developed drugs. He says that the new drugs which are inhibitors of NS3/4A protease must be combined with interferon- and ribavirin because the virus can overcome easily a single antiviral....

  • All-oral hep. C combos threaten interferon. Iskowitz, Marc // Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p16 

    The article focuses on the development of an oral drug for treating hepatitis C virus. According to a clinical trial, an all-oral therapy joining daclatasvir from BMS and Gilead Sciences Inc.'s GS-7977 has suppressed the virus in more than 95 percent of patients across a broad spectrum of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics